Back to Directory
Eptifibatide
Performance & EnduranceAntiplatelet peptide used for acute coronary syndromes, prevents blood clots.
Key Benefits
- ✓Prevents blood clots
- ✓Reduces heart attack risk
- ✓Used during cardiac procedures
- ✓Antiplatelet effects
- ✓Improves outcomes in ACS
Dosing Information
Dosage Range
180 mcg/kg bolus
Frequency
Continuous IV infusion
Typical Duration
12-96 hours
Detailed Protocol
Administered via intravenous infusion in hospital settings during acute coronary events or PCI. Medical use only under close monitoring.
About Eptifibatide
Eptifibatide (Integrilin) is a synthetic heptapeptide that inhibits platelet aggregation by blocking the glycoprotein IIb/IIIa receptor. FDA-approved for acute coronary syndromes and during percutaneous coronary intervention (PCI).
Research Notes
FDA-approved in 1998 for acute coronary syndromes. Extensive clinical use shows reduced cardiovascular events during PCI. Hospital use only.
Potential Side Effects
- •Bleeding risk
- •Thrombocytopenia
- •Injection site hematoma
- •Requires hospital monitoring
Always consult with a healthcare professional before starting any peptide therapy.